The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study

Status Completed

Clinical Trial Summary

The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.

Clinical Trial Description

MDS is a hematologic malignancy characterized by cytopenias, bone marrow failure, and a risk of transformation to acute myeloid leukemia (AML). HSCT is the only curative therapy for MDS. Despite its increasing use among older patients (age greater than 60), more data are needed to assess outcomes of HSCT in older adults compared to other therapies. In this observational study, patients with MDS presenting at the study institutions are screened for disease characteristics that indicate that they are potentially appropriate for HSCT (both high-risk disease and fit for the procedure). Patients who meet inclusion and exclusion criteria and agree to participate in the study are entered into a clinical database and followed for overall survival. Patients also complete quality of life (QoL) assessments at enrollment and two years afterward, with the goal of investigating potential relationships between QoL and MDS treatment (HSCT vs. non-HSCT strategies). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02390414
Study type	Observational
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase
Start date	May 2011
Completion date	September 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02550535` - A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients	Phase 1/Phase 2
Completed	`NCT00186342` - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies	N/A
Completed	`NCT00528983` - Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia	Phase 1
Completed	`NCT01355913` - Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
Withdrawn	`NCT04985656` - A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes	Phase 2
Completed	`NCT01736683` - Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)	Phase 2
Completed	`NCT02333058` - Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies	Phase 2
Completed	`NCT01135849` - B-Receptor Signaling in Cardiomyopathy	N/A
Withdrawn	`NCT04395092` - Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)	Phase 2
Completed	`NCT01885897` - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT	Phase 1/Phase 2
Recruiting	`NCT05092451` - Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances	Phase 1/Phase 2
Recruiting	`NCT05884333` - Cord Blood Transplant in Adults With Blood Cancers	Phase 2
Completed	`NCT01326377` - ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS)	Phase 2
Completed	`NCT02966782` - A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)	Phase 1
Recruiting	`NCT02779569` - A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)	N/A
Recruiting	`NCT02099669` - Red Blood Cell Transfusion Thresholds and QOL in MDS	N/A
Completed	`NCT01392989` - Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders	Phase 2
Not yet recruiting	`NCT06398457` - Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies	Early Phase 1
Recruiting	`NCT02775383` - The National Myelodysplastic Syndromes (MDS) Study
Recruiting	`NCT04275518` - A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.	Phase 1